European Medicines Agency (EMA) Regulation
Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products
- Stage
- In force, reached 3 Aug 2026
- In force
- In force since 20 May 2004 · CELEX 32004R0726
- Procedure
- Regulation
- Last activity
- 3 Aug 2026
Where it stands
Latest: Delegated act published: Correcting acts, 3 Aug 2026.
- 3 Aug 2026
- Delegated act published: Correcting acts
Delegated and implementing acts beneath it
By status: 3 published.
| Act | Kind | Status | Adoption |
|---|---|---|---|
| Commission Delegated Regulation (EU) 2026/863 | Delegated · Regulation | Published | |
| Commission Delegated Regulation (EU) 2024/1701 | Delegated · Regulation | Published | Q1 2024 |
| Commission Delegated Regulation (EU) 2021/756 | Delegated · Regulation | Published | Q1 2021 |
Titles link to EUR-Lex where the act has been published.
Summary
GeneratedRegulation (EC) No 726/2004 establishes the EU centralized procedure for authorizing and supervising medicinal products for human use and creates the European Medicines Agency. It applies from 20 November 2005, with certain annex provisions from 20 May 2008. The regulation affects pharmaceutical companies seeking EU-wide marketing authorizations, national authorities, and the EMA.
What the workspace adds on this file
Everything above is the public record. Subscribers see this page with their own layer on top.
Why it matters to you
What moved
Your contacts on it
A first draft
Sources: EUR-Lex. Record as of 14 Sept 2026. Something wrong on this page? Report an error.
Request access
See this file with your own layer on top: why it matters to you, your contacts on it and a first draft. We’ll schedule a 20-minute walkthrough.
EU-hosted · GDPR-compliant · Trust Center →
By submitting, you agree to our privacy policy.